RT Journal Article
T1 GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours.
A1 Rico, Mikel
A1 Flamarique, Sonia
A1 Casares, Cristina
A1 García, Tamara
A1 López, Miriam
A1 Martínez, Maribel
A1 Serrano, Javier
A1 Blanco, Manuel
A1 Hernanz, Raúl
A1 de Ingunza-Barón, Lourdes
A1 Marcos, Francisco José
A1 Couñago, Felipe
K1 Chemotherapy
K1 Guidelines
K1 Radiotherapy
K1 Reirradiation
K1 Targeted therapies
K1 Thymic epithelial tumors
AB Thymic epithelial tumours (TET) are rare, heterogeneous neoplasms that range from resectable indolent tumours to aggressive thymic carcinomas with a strong tendency to metastasize. The pathological diagnosis is complex, in part due to the existence of several different classification systems. The evidence base for the management of TETs is scant and mainly based on non-randomised studies and retrospective series. Consequently, the clinical management of TETs tends to be highly heterogenous, which makes it difficult to improve the evidence level. The role of technological advances in the field of radiotherapy and new systemic therapies in the treatment of TETs has received little attention to date. In the present clinical guidelines, developed by the GOECP/SEOR, we review recent developments in the diagnosis and classification of TETs. We also present a consensus-based therapeutic strategy for each disease stage that takes into consideration the best available evidence. These guidelines focus primarily on the role of radiotherapy, including recent advances, in the management of TETs. The main aim of this document is to promote the standardisation of clinical practice and lay the foundations for future studies to clarify the main unresolved questions related to the optimal management of TET.
SN 2218-4333
YR 2021
FD 2021
LK https://hdl.handle.net/10668/24970
UL https://hdl.handle.net/10668/24970
LA en
DS RISalud
RD Apr 10, 2025